# Metastatic Castration-Resistant Prostate Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/metastatic-castration-resistant-prostate-cancer

> 16 upcoming FDA catalysts in metastatic Castration-Resistant Prostate Cancer: mevrometostat (PFE) on Sep to Dec 2027 (topline data readout); BMS-986365 (BMY) on Sep to Dec 2027 (topline data readout); BMS-986365 (BMY) on September 2027 (primary completion); mevrometostat (PFE) on September 2027 (primary completion); and 12 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 10, 2025 | [Vudalimab + carboplatin + cabazitaxel primary completion](https://sec-api.dev/pdufa/vudalimab-carboplatin-cabazitaxel) | XNCR | Metastatic Castration-Resistant Prostate Cancer | completed | "NCT05005728 (XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-10 (ACTUAL); Lead Sponsor Xencor, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05005728)) |
| December 7, 2025 | [TLX591 trial start](https://sec-api.dev/pdufa/tlx591) | TLX | metastatic castration resistant prostate cancer | completed | "Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosopatamab tetraxetan) in patients with metastatic castration resistant prostate cancer (mCRPC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000073/prostactpr.htm)) |
| October 6, 2026 | [Carotuximab interim data readout](https://sec-api.dev/pdufa/carotuximab) | KAPA | metastatic castration-resistant prostate cancer | completed, positive | "ANGELES — October 6, 2026 — Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1962011/000149315226045844/ex99-1.htm)) |
| Sep to Dec 2027 | [Mevrometostat topline data readout](https://sec-api.dev/pdufa/mevrometostat) | PFE | Metastatic Castration-Resistant Prostate Cancer | scheduled | "NCT06629779 (A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06629779)) |
| Sep to Dec 2027 | [BMS-986365 topline data readout](https://sec-api.dev/pdufa/bms-986365) | BMY | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT06764485 (A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-12 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764485)) |
| September 2027 | [BMS-986365 primary completion](https://sec-api.dev/pdufa/bms-986365) | BMY | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT06764485 (A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-12 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764485)) |
| September 2027 | [Mevrometostat primary completion](https://sec-api.dev/pdufa/mevrometostat) | PFE | Metastatic Castration-Resistant Prostate Cancer | scheduled | "NCT06629779 (A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06629779)) |
| December 2027 | [177lu-tlx591 primary completion](https://sec-api.dev/pdufa/177lu-tlx591) | TLX | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT06520345 (The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06520345)) |
| Dec 2027 to Mar 2028 | [177lu-tlx591 topline data readout](https://sec-api.dev/pdufa/177lu-tlx591) | TLX | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT06520345 (The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06520345)) |
| Mar to Jun 2028 | [FG-3246 topline data readout](https://sec-api.dev/pdufa/fg-3246) | KYNB | Metastatic Castration-Resistant Prostate Cancer | scheduled | "NCT06842498 (A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Kyntra Bio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06842498)) |
| March 2028 | [Rinzimetostat primary completion](https://sec-api.dev/pdufa/rinzimetostat) | ORIC | Metastatic Castration Resistant Prostate Cancer | scheduled | "NCT07723248 (A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor ORIC Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07723248)) |
| Mar to Jun 2028 | [Rinzimetostat topline data readout](https://sec-api.dev/pdufa/rinzimetostat) | ORIC | Metastatic Castration Resistant Prostate Cancer | scheduled | "NCT07723248 (A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor ORIC Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07723248)) |
| March 2028 | [FG-3246 primary completion](https://sec-api.dev/pdufa/fg-3246) | KYNB | Metastatic Castration-Resistant Prostate Cancer | scheduled | "NCT06842498 (A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Kyntra Bio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06842498)) |
| Jan to Apr 2029 | [Xaluritamig topline data readout](https://sec-api.dev/pdufa/xaluritamig) | AMGN | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT06691984 (Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-02 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06691984)) |
| January 2029 | [Xaluritamig primary completion](https://sec-api.dev/pdufa/xaluritamig) | AMGN | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT06691984 (Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-02 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06691984)) |
| Jun to Sep 2029 | [Xofigo topline data readout](https://sec-api.dev/pdufa/xofigo) | AZN | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT07611110 (AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07611110)) |
| June 2029 | [Xofigo primary completion](https://sec-api.dev/pdufa/xofigo) | AZN | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT07611110 (AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07611110)) |
| Jan to Apr 2030 | [Xaluritamig topline data readout](https://sec-api.dev/pdufa/xaluritamig) | AMGN | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT07213674 (A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-07 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07213674)) |
| January 2030 | [Xaluritamig primary completion](https://sec-api.dev/pdufa/xaluritamig) | AMGN | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT07213674 (A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-07 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07213674)) |

## Drugs

- [Vudalimab + carboplatin + cabazitaxel](https://sec-api.dev/pdufa/vudalimab-carboplatin-cabazitaxel) (XNCR)
- [TLX591](https://sec-api.dev/pdufa/tlx591) (TLX)
- [Carotuximab](https://sec-api.dev/pdufa/carotuximab) (KAPA)
- [Mevrometostat](https://sec-api.dev/pdufa/mevrometostat) (PFE)
- [BMS-986365](https://sec-api.dev/pdufa/bms-986365) (BMY)
- [177lu-tlx591](https://sec-api.dev/pdufa/177lu-tlx591) (TLX)
- [FG-3246](https://sec-api.dev/pdufa/fg-3246) (KYNB)
- [Rinzimetostat](https://sec-api.dev/pdufa/rinzimetostat) (ORIC)
- [Xaluritamig](https://sec-api.dev/pdufa/xaluritamig) (AMGN)
- [Xofigo](https://sec-api.dev/pdufa/xofigo) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/metastatic-castration-resistant-prostate-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Metastatic Castration-Resistant Prostate Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/metastatic-castration-resistant-prostate-cancer

```bibtex
@misc{secapidev_indications_metastatic_castration_resistant_prostate_cancer_20261116,
  title        = {Metastatic Castration-Resistant Prostate Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/metastatic-castration-resistant-prostate-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_metastatic_castration_resistant_prostate_cancer_20261116","title":"Metastatic Castration-Resistant Prostate Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/metastatic-castration-resistant-prostate-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
